PharmStars, a digital health accelerator focused on forging relationships between digital health companies and the life science world, has announced the culmination of its first 10-week program focused on the theme “Innovations in Clinical Trials.”
The first cohort, including Droice Labs, was selected in September 2021 following a competitive application process. More than 70 companies representing 18 countries applied for 10 slots in the first cohort of accelerator participants.
The Showcase Event brought together the participating startups and PharmStars’ innovation-minded pharma members. PharmStars’ six life science members include Boehringer Alexion AstraZeneca Rare Disease, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sumitovant Biopharma and Takeda Pharmaceutical Company Limited.
Read more here – Mobihealth, Medcity news
